Last updated on June 2018

A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Chronic Myeloid Leukemia
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other:
    at the age of 18 or more
    newly diagnosed within three months as a Chronic Myeloid Leukemia
    with positive Philadelphia chromosome and appearance of BCR-ABL transcript
    with 0 - 2 of ECOG Performance Status
    with normal renal function
    with normal hepatic function
    able to understand and decide to involve the study

You may not be eligible for this study if the following are true:

  • history of radiation therapy for more than 25% of bone marrow due to other malignant
    history of other clinically relevant malignant tumors
    with bleeding disorders which are not related to leukemia
    evidence of clinically relevant cardiac dysfunction
    with severe disease which cannot be regulated by other organs
    a previous administration of Imatinib more than a week prior to the first dose.
    participation in other drug study(eg. intervention trial) within 30 days prior to the
    creening visit
    females with pregnancy, childbearing or lactating potential
    other reasons determined by investigators

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.